In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...
The approval was based on the SOUL trial, which evaluated oral semaglutide in adults 50 years and older with T2DM and established CV disease and/or chronic kidney disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback